<unk>  is a CD22-directed cytotoxin that is FDA approved for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include infusion-related reactions, edema, nausea, fatigue, headache, pyrexia, constipation, anemia, and diarrhea. Most common (≥ 50%) laboratory abnormalities are creatinine increased, ALT increased, hypoalbuminemia, AST increased, hypocalcemia, and hypophosphatemia.
Moxetumomab pasudotox-tdfk
Tisotumab vedotin-tftv
Cemiplimab-rwlc
Fremanezumab-vfrm
Vincristine liposome
Ado-trastuzumab emtansine
Cytarabine liposome
Galcanezumab-gnlm